NASDAQ:ABEO

Abeona Therapeutics Stock Forecast, Price & News

$1.19
-0.02 (-1.65 %)
(As of 09/22/2021 04:00 PM ET)
Add
Compare
Today's Range
$1.17
$1.24
50-Day Range
$1.15
$1.35
52-Week Range
$0.99
$3.79
Volume539,291 shs
Average Volume2.26 million shs
Market Capitalization$120.46 million
P/E RatioN/A
Dividend YieldN/A
Beta1.43
30 days | 90 days | 365 days | Advanced Chart
Receive ABEO News and Ratings via Email

Sign-up to receive the latest news and ratings for Abeona Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Abeona Therapeutics logo

About Abeona Therapeutics

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.98 out of 5 stars

Medical Sector

603rd out of 1,352 stocks

Pharmaceutical Preparations Industry

293rd out of 665 stocks

Analyst Opinion: 3.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Abeona Therapeutics (NASDAQ:ABEO) Frequently Asked Questions

Is Abeona Therapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abeona Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Abeona Therapeutics stock.
View analyst ratings for Abeona Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Abeona Therapeutics?

Wall Street analysts have given Abeona Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Abeona Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Abeona Therapeutics' next earnings date?

Abeona Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Abeona Therapeutics
.

How were Abeona Therapeutics' earnings last quarter?

Abeona Therapeutics Inc (NASDAQ:ABEO) issued its earnings results on Thursday, July, 29th. The biopharmaceutical company reported ($0.16) EPS for the quarter, meeting analysts' consensus estimates of ($0.16).
View Abeona Therapeutics' earnings history
.

How has Abeona Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Abeona Therapeutics' stock was trading at $2.19 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ABEO shares have decreased by 45.7% and is now trading at $1.19.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ABEO?

4 brokers have issued 1-year price objectives for Abeona Therapeutics' shares. Their forecasts range from $3.00 to $5.00. On average, they expect Abeona Therapeutics' stock price to reach $4.25 in the next twelve months. This suggests a possible upside of 257.1% from the stock's current price.
View analysts' price targets for Abeona Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Abeona Therapeutics' key executives?

Abeona Therapeutics' management team includes the following people:
  • Mr. Steven H. Rouhandeh, Exec. Chairman (Age 61)
  • Dr. Timothy J. Miller, Pres, Chief Scientific Officer & Director (Age 46)
  • Mr. Jeffrey Blaine Davis, Chief Operating Officer (Age 55)
  • Mr. Carsten Thiel, Chief Exec. Officer (Age 54)
  • Mr. Stephen B. Thompson, Sr. VP of Fin. and Admin., Chief Accounting Officer, Sec. & Treasurer (Age 64)

Who are some of Abeona Therapeutics' key competitors?

What other stocks do shareholders of Abeona Therapeutics own?

What is Abeona Therapeutics' stock symbol?

Abeona Therapeutics trades on the NASDAQ under the ticker symbol "ABEO."

Who are Abeona Therapeutics' major shareholders?

Abeona Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.68%), JPMorgan Chase & Co. (2.00%), Morgan Stanley (1.79%), Morgan Stanley (1.79%), BlackRock Inc. (1.63%) and Millennium Management LLC (1.35%). Company insiders that own Abeona Therapeutics stock include Edward Carr, Michael Amoroso, Paul Elliot Mann, Sco Capital Partners Llc, Stefano Buono and Todd Wider.
View institutional ownership trends for Abeona Therapeutics
.

Which major investors are selling Abeona Therapeutics stock?

ABEO stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Northern Trust Corp, Geode Capital Management LLC, Los Angeles Capital Management LLC, Bank of New York Mellon Corp, Charles Schwab Investment Management Inc., and Dimensional Fund Advisors LP. Company insiders that have sold Abeona Therapeutics company stock in the last year include Edward Carr, Michael Amoroso, Paul Elliot Mann, Sco Capital Partners Llc, and Todd Wider.
View insider buying and selling activity for Abeona Therapeutics
or view top insider-selling stocks.

Which major investors are buying Abeona Therapeutics stock?

ABEO stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Morgan Stanley, Morgan Stanley, Russell Investments Group Ltd., Vanguard Group Inc., Tibra Equities Europe Ltd, Goldman Sachs Group Inc., and Ergoteles LLC.
View insider buying and selling activity for Abeona Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Abeona Therapeutics?

Shares of ABEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Abeona Therapeutics' stock price today?

One share of ABEO stock can currently be purchased for approximately $1.19.

How much money does Abeona Therapeutics make?

Abeona Therapeutics has a market capitalization of $120.46 million and generates $10 million in revenue each year. The biopharmaceutical company earns $-84,230,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis.

What is Abeona Therapeutics' official website?

The official website for Abeona Therapeutics is www.abeonatherapeutics.com.

Where are Abeona Therapeutics' headquarters?

Abeona Therapeutics is headquartered at 3333 LEE PARKWAY SUITE 600, DALLAS TX, 75219.

How can I contact Abeona Therapeutics?

Abeona Therapeutics' mailing address is 3333 LEE PARKWAY SUITE 600, DALLAS TX, 75219. The biopharmaceutical company can be reached via phone at 214-665-9495 or via email at [email protected].


This page was last updated on 9/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.